Investigational DAA treatment combination effective and improves patient-reported outcomes
(European Association for the Study of the Liver) Analysis of patient outcome data from the POLARIS-1, 2, 3 and 4 studies demonstrate that patients with HCV and cirrhosis have greatest improvements of PRO scores when taking treatment with sofosbuvir + velpatasvir, ± voxilaprevir, an anti-HCV regimen that has been shown to be safe and effective against all HCV genotypes. The analysis, presented at The International Liver Congress 2017 in Amsterdam, The Netherlands, showed that achievement of SVR12 was associated with improvements in PROs.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news